Skip to content
Back to meeting Original
CancerTherapyAdvisor· @CancerTherAdvsr · X·· 2 hours agoScore70

KRASCENDO

Body

Krascendo 1 trial: Patients with previously treated advanced/metastatic KRAS G12C-altered #NSCLC, divarasib therapy improves survival outcomes compared with sotorasib or adagrasib.

Presented at #ESMO26 and published in @NEJM, read the data:
https://bit.ly/4ztZSgZ

11 views · 1 like · 1 repost · 0 replies

Conference abstracts

Source: CancerTherapyAdvisor · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.